anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ulcerative colitis (UC) is a common form of inflammatory bowel disease (IBD) that consists of chronic inflammatory disorders of the colon and the small intestine with unknown etiology. Chronic inflammation is the basis of complicated pathogenesis, and the course of the disease is often complicated by an immune response. Malnutrition, malabsorption and the involvement of organs other than those of the gastrointestinal tract are frequent consequences of the disease . Although extra-intestinal manifestations of IBD are common (ranging from 6% to 47%), cardiac involvement is rare.

Inflammatory bowel disease (IBD) is a known risk factor for cardiovascular disease (CVD). IBD patients have a two- to threefold increased risk of venous thromboembolism, particularly during acute flares when disrupted homeostasis of anti- and procoagulants leads to a hypofibrinolytic state. Cardiovascular manifestations in Crohn's disease (CD) and ulcerative colitis (UC) include conditions such as Takayasu's arteritis, pericarditis, and myocarditis. Chronic inflammation and altered lipid metabolism, along with long-term use of anti-inflammatory drugs (e.g., corticosteroids, TNF-α inhibitors), are thought to drive CV pathology in IBD. Additionally, chronic inflammation is linked to pathological collagen deposition in affected organs.

Although conventional echocardiography is a widely accessible and easy tool to detect cardiac abnormalities, novel echocardiographic techniques and indices offer easy, reproducible and quantitative information for evaluating left ventricle function and subclinical changes . Speckle tracking echocardiography (STE) is an advanced echocardiographic methodology for the quantification of myocardial function. STE has been successfully used to identify early subclinical cardiac involvement in a variety of asymptomatic populations with chronic diseases and unremarkable conventional echocardiography. Unlike earlier echocardiography techniques, two-dimensional speckle tracking echocardiography (2DSTE) is less angle-dependent. In addition, STE is not affected by the rotation of the heart and allows heart functions to be examined segment by segment from various echocardiographic views . Despite, studies have examined subclinical cardiac impairment in patients with IBD, to the best of our knowledge, none have explored the impact of ulcerative colitis activity on cardiac function through using STE.
The anti-angiogenic functions of a polysulfated, cyclic compound; ST104P, were investigated. ST104P exhibited excellent water solubility and low cytotoxicity to endothelial cells. ST104P potently inhibited the secretion of matrix metalloproteinase (MMPs) by endothelial cells. Moreover, ST104 also perturbed the migration and tube formation of endothelial cells. Application of ST 104P abolished the neovascularization in chicken choroiallantoic membrane (CAM) in a dose-dependent manner. Besides, repeated administration of ST104P into Lewis lung carcinoma resulted in delayed tumor growth and prolonged the life span of tumor-bearing mice. These results indicated that ST104P inhibited angiogenesis and may hold promises for treatment of cancer.
A composition for promoting hair growth or preventing hair loss is provided to improve the effects of promoting hair growth and preventing hair loss and reduce scalp irritation using Sasa borealis extract and pine needle extract. A composition for promoting hair growth or preventing hair loss comprises one or more extract selected among Sasa borealis extract and pine needle extract. The composition comprises both Sasa borealis extract and pine needle extract. The composition is shampoo, hair cream, or soap. The shampoo further comprises an acceptable carrier. The carrier comprises the surfactant, bubble enhancer, emulsifier, and hydrotrope.
Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
FIELD: medicine, gastroenterology. SUBSTANCE: invention relates to experimental abdominal surgery. Method involves administration of 1 ml of colloidal solution containing 0.02 g of food chitosan "Amidan" of molecular mass 10 000-15 000 Da and deacetylation degree 90-95% in gastroenteric tract, three times per a day. The method allows to relieve the severe inflammatory blood response and reduce lethality. Invention can be used for prophylaxis and treatment of severe destructive forms of pancreatitis. EFFECT: enhanced effectiveness of treatment. 4 dwg, 1 tbl
This invention discloses a bifunctional TGF-B/immune checkpoint fusion gene and protein with anti-inflammatory activity that represents a new class of therapy for Immune disorders, immune dysregulation, and autoimmune diseases. The bifunctional TGF-B/immune checkpoint fusion gene and protein include: (i) a TGF-B domain consists of TGF-B1 (ii) an immune checkpoint consisting of PD-L1, (iii) a flexible peptide linker that links two TGF-B domains resulting in a dimeric TGF-B construct wherein the dimeric form of the TGF-B ligand is important for its binding and functional activity, and (iv) a rigid peptide linker, wherein the dimeric TGF-B ligand is linked to the immune checkpoint ligand.A unique feature of this invention is the engineering of a dimeric TGF-B1 domain in the TGF-B1/PD-L1 fusion protein which was experimentally shown to be important in its binding to its TFGBR1 receptor and its functional activity. The functional domains of the fusion protein act in concert to maintain tolerance for self-antigens by stimulating regulatory cells and to regulate the activities of effector cells, respectively. The immune regulatory activity of the bifunctional TGF-B/immune checkpoint fusion gene and protein was demonstrated using a TGF-B1/PD-L1 fusion pair, showing that the domains functionally bind their respective receptors and inhibit NF-kB activation in a reporter assay, downregulate NF-kB-responsive genes, suppress the growth of PHA/IFN-γ-activated effector-like Jurkat T cells with subsequent upregulation of Foxp3 and downregulation of NF-kB1 and IL-6. The fusion protein described in this invention elicits a high frequency of cell-to-cell contact that induced upregulation of Treg-associated markers (Foxp3 and IL2RA). The bifunctional fusion protein described herein modulates immune reactions and represents a new class of therapy for Immune disorders, immune dysregulation, and autoimmune diseases.
Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
BACKGROUND: Chronic kidney disease (CKD) is highly prevalent in Central America, and genetic factors may contribute to CKD risk. To understand the influences of genetic admixture on CKD susceptibility, we conducted an admixture mapping screening of CKD traits and risk factors in US Hispanic and Latino individuals from Central America country of origin.
METHODS: We analyzed 1023 participants of HCHS/SOL (Hispanic Community Health Study/Study of Latinos) who reported 4 grandparents originating from the same Central America country. Ancestry admixture findings were validated on 8191 African Americans from WHI (Women's Health Initiative), 3141 American Indians from SHS (Strong Heart Study), and over 1.1 million European individuals from a multistudy meta-analysis.
RESULTS: We identified 3 novel genomic regions for albuminuria (chromosome 14q24.2), CKD (chromosome 6q25.3), and type 2 diabetes (chromosome 3q22.2). The 14q24.2 locus driven by a Native American ancestry had a protective effect on albuminuria and consisted of 2 nearby regions spanning the RGS6 gene. Variants at this locus were validated in American Indians. The 6q25.3 African ancestry-derived locus, encompassing the ARID1B gene, was associated with increased risk for CKD and replicated in African Americans through admixture mapping. The European ancestry type 2 diabetes locus at 3q22.2, encompassing the EPHB1 and KY genes, was validated in European individuals through variant association.
CONCLUSIONS: US Hispanic/Latino populations are culturally and genetically diverse. This study focusing on Central America grandparent country of origin provides new loci discovery and insights into the ancestry-of-origin influences on CKD and risk factors in US Hispanic and Latino individuals.
Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
PURPOSE: A composition containing Gentianae macrophyllae Radix extract for preventing or treating dental caries is provided to ensure excellent antibacterial effect with persistence and safety. CONSTITUTION: A composition for preventing or treating dental caries contains 0.01-50 wt% of Gentianae macrophyllae Radix extract as an active ingredient, isolated using water or an organic solvent. The organic solvent is ethanol or an ethanol solution. The extract also includes a fraction which is prepared from the water extract of Gentianae macrophyllae Radix using an organic solvent. The organic solvent is ethylacetate or butanol. A health food for preventing or relieving dental caries contains the extract as an active ingredient. The health food is a food or beverage. [Reference numerals] (AA) Gentianae macrophyllae Radix
OBJECTIVE: Serum luteinising hormone (LH) concentration has been reported to be lower in girls with overweight and obesity (OW/OB) as compared with girls with normal weight (NW). This study aimed to evaluate peak serum LH concentration during gonadotropin-releasing hormone analogue (GnRHa) test in girls with OW/OB and NW who had central precocious puberty (CPP) and to determine peak serum LH cut-off for diagnosing CPP in girls with OW/OB.
DESIGN, PATIENTS AND MEASUREMENTS: Medical records of 971 girls with premature breast development who underwent subcutaneous GnRHa (100 µg of triptorelin acetate) test were reviewed. All girls were classified as either CPP or premature thelarche. All of them were further classified into two groups according to their body mass index as NW and OW/OB groups for each Tanner stage.
RESULTS: There were 634 and 337 girls in NW and OW/OB groups, respectively. CPP was diagnosed in 600 girls (249 had Tanner stage II and 351 had Tanner stage III). There were no differences in peak serum LH concentrations between CPP girls with NW and OW/OB. Peak serum LH cut-off of 5 IU/L (the current widely used cut-off) had a sensitivity and a specificity of 75% and 90%, respectively in NW group. Peak serum LH cut-off for CPP diagnosis was lower at 4 IU/L in the OW/OB group with greater sensitivity and specificity of 86% and 93%, respectively. The results were reproducible for each Tanner stage of breasts.
CONCLUSION: Lower peak serum LH cut-off to 4 IU/L for diagnosing CPP in girls with OW/OB should be considered to avoid underdiagnosis of the condition.
Methocarbamol tablets USP a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11H 15NO 5. Its molecular weight is 241.24. The structural formula is shown below. 

Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n-hexane.

Methocarbamol tablets USP are available as 500 mg and 750 mg tablets for oral administration. Methocarbamol tablets USP 500 mg and 750 mg contain the following inactive ingredients: sodium lauryl sulfate, sodium starch glycolate, povidone K 90, polyethylene glycol, magnesium stearate, colloidal silicon dioxide, low substituted hydroxypropyl cellulose and stearic acid.
PURPOSE: A method and composition for promoting skin regeneration using icariside II is provided to promote proliferation of transient amplifying cells of epidermis base and promote skin regeneration. CONSTITUTION: An icariside II of chemical formula 1 promotes proliferation of skin cells in skin cells. The skin cell is transient amplifying cells(TA cells). A composition for promoting skin regeneration contains the icariside II as an active ingredient. The content of the active ingredient is 0.001-10 weight% based on total weight. The composition regenerates epidermis by promoting proliferation of the TA cells. The composition increases the number of TA cells which express CD71 protein (Cluster of Differentiation 71 Protein) and α6 integrin. The composition increases the expression of CD200(Cluster of Differentiation 200).
The growing financial burden of noncommunicable diseases (NCDs) in sub-Saharan Africa (SSA) hinders the attainment of the sustainable development goals. However, there has been no updated synthesis of evidence in this regard. Therefore, our study summarizes the current evidence in the literature and identifies the gaps. We systematically search relevant databases (PubMed, Scopus, ProQuest) between 2015 and 2023, focusing on empirical studies on NCDs and their financial burden indicators, namely, catastrophic health expenditure (CHE), impoverishment, coping strategies, crowding-out effects and unmet needs for financial reasons (UNFRs) in SSA. We examined the distribution of the indicators, their magnitudes, methodological approaches and the depth of analysis. The 71 included studies mostly came from single-country (n = 64), facility-based (n = 52) research in low-income (n = 22), lower-middle-income (n = 47) and upper-middle-income (n = 10) countries in SSA. Approximately 50% of the countries lacked studies (n = 25), with 46% coming from West Africa. Cancer, cardiovascular disease (CVD) and diabetes were the most commonly studied NCDs, with cancer and CVD causing the most financial burden. The review revealed methodological deficiencies related to lack of depth, equity analysis and robustness. CHE was high (up to 95.2%) in lower-middle-income countries but low in low-income and upper-middle-income countries. UNFR was almost 100% in both low-income and lower-middle-income countries. The use of extreme coping strategies was most common in low-income countries. There are no studies on crowding-out effect and pandemic-related UNFR. This study underscores the importance of expanded research that refines the methodological estimation of the financial burden of NCDs in SSA for equity implications and policy recommendations.
A comparative study was carried out to analyze the number of syncytial knots and the intensity of expression of vascular endothelial growth factor (VEGF) in the villi of the monochorionic diamniotic placenta in pregnancies complicated by the syndrome of selective fetal growth restriction (sFGR). We performed a morphological analysis of 32 monochorionic diamniotic placentas after term delivery which were divided into two groups. The main group included the placentas of 15 puerperas whose pregnancies were complicated by sFGR. The control group included twin placentas of 17 puerperas without signs of sFGR. The number of syncytial knots was determined by histological studies, and the levels of VEGF expression in syncytiotrophoblast and capillary endotheliocytes of the placental villi were determined by immunohistochemical studies. The study showed an increase in the number of syncytial knots in the villi of the placental part of the fetus with sFGR which indicated the development of preplacental hypoxia. A significant increase in the level of VEGF expression in the syncytiotrophoblast and vascular endothelium of the villi should be considered as a manifestation of a compensatory adaptational response to hypoxia, though it is insufficient to prevent the development of sFGR.
The effectiveness of KONVOMEP has been established, in part, based on studies of another omeprazole and sodium bicarbonate oral suspension product for the reduction of risk of upper GI bleeding in critically ill adult patients.

A double-blind, multicenter, randomized, non-inferiority clinical trial was conducted to compare omeprazole and sodium bicarbonate oral suspension 40 mg/1680 mg and intravenous cimetidine for the reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients (mean APACHE II score = 23.7). The primary endpoint was significant upper GI bleeding defined as bright red blood which did not clear after adjustment of the nasogastric tube and a 5 to 10 minutes lavage, or persistent Gastroccult positive coffee grounds for 8 consecutive hours which did not clear with 100 mL lavage. Omeprazole and sodium bicarbonate oral suspension was administered as two doses of 40 mg omeprazole and 1680 mg sodium bicarbonate 6 to 8 hours apart on the first day via orogastric or nasogastric tube, followed by 40 mg omeprazole and 1680 mg sodium bicarbonate once daily thereafter. Cimetidine was administered intravenously as a 300 mg bolus, followed by 50 to 100 mg/hour continuously thereafter. Treatment was administered for up to 14 days (mean = 6.8 days). A total of 359 patients were studied, age range 16 to 91 years (mean age of 56 years), 58.5% were males, and 64% were Caucasians. The results of the study showed that omeprazole and sodium bicarbonate oral suspension was non-inferior to intravenous cimetidine, 7/178 (3.9%) patients in the omeprazole and sodium bicarbonate oral suspension group vs. 10/181 (5.5%) patients in the cimetidine group experienced clinically significant upper GI bleeding.
Approval was obtained from the ethics committee of three healthcare institutions. A process of informed consent will be conducted with all participants, and confidentiality and data protection will be guaranteed. A research assistant, unaware of the operational hypotheses and study objectives, will execute the experiment and record the results. There will be no blinding of the intervention for the participants or the assistant. At each institution, randomization will be conducted a priori to determine the operating room where participants should be recruited. Likewise, the intervention to be administered will be randomized. All these data will be stored in opaque envelopes that will be opened at the time of recruitment. A total of 72 participants will be recruited, with 36 exposed to drying with one towel and 36 to drying with two towels. Recruitment will cease upon completion of the respective participants stipulated for each intervention.

The primary outcome of interest will be the presence or absence of contamination. To evaluate this outcome, the gold standard would be the collection of cultures and the analysis of the presence or absence of bacterial contamination. However, due to the costs and methodological difficulties of taking cultures, an indirect method, previously validated as a surrogate, will be employed instead. 2 mL of fluorescent cream (Glo Germ ™) will be applied with a brush proximal to the normally washed area during surgical scrubbing (3 cm above the elbow). Participants will be shown a video on how to dry with one or two surgical towels and will be given one minute to do so. Subsequently, the presence or absence of fluorescent cream on the upper extremities will be evaluated using a UV light lamp. If fluorescence is evidenced in the washed area where it was not applied, it will be considered that there was contamination during the hand drying process.

No interim analyses will be executed. Data will be de-identified for the analysis. Descriptive statistics will be conducted using R studio, and proportions of contamination when drying with one or two towels will be compared. A simple logistic regression will be performed to assess the relationship between the intervention and the proportion of contamination events, and a multivariate logistic regression will be conducted to assess the effect of confounding variables on the outcome. The results will be reported collectively for publication in a peer-reviewed journal.
This group included participants that were withdrawn from CAB LA+RPV LA IM regimens based on protocol criteria and were required to access Highly Active Antiretroviral Therapy (HAART) of choice. Participants were followed up for approximately 52 weeks.
Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, fibromyalgia, and combinations thereof. The compounds act by acting as selective antagonist to the kappa (κ) opioid receptor. Further, disclosed compounds are an analog compound that can act as an antagonist to one or more opioid receptors. When present, these compounds lead to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner. The disclosed compounds are shown to be effective in the nanomolar range.
Controlled release pharmaceutical compsns. are obtained by adding the diluted active ingredients to Konjak mannans, treating the mixture with a surfactant and, after homogenisation, spraying the product and converting it to the desired dry form. Konjak mannans is an alimentary flour obtained from roots of Amorphophallus konjak and comprises uronic acid molecules. The amount of this material used is preferably 100 mg- 2 g per unit dose. The surfactant is preferably ionic, such as sodium lauryl sulphate, 0.5-7.5 mg being used per unit dose. The physical forms of the product may be a powder, granule or tablet for oral admin. The active ingredient may be a beta-lactam antibiotic, a neurotropic agent, an anti-tussive, an enzyme inhibitor, a beta blocker, a bronchodilator or an anti-inflammatory.
1\. Very rare cases of hyponatremia have been reported from world-wide postmarketing experience in patients treated with DDAVP (desmopressin acetate). DDAVP is a potent antidiuretic which, when administered, may lead to water intoxication and/or hyponatremia. Unless properly diagnosed and treated hyponatremia can be fatal. Therefore, fluid restriction is recommended and should be discussed with the patient and/or guardian. Careful medical supervision is required.

2\. When DDAVP Tablets are administered, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward to decrease the potential occurrence of water intoxication and hyponatremia. (See PRECAUTIONS, Pediatric Use and Geriatric Use.) All patients receiving DDAVP therapy should be observed for the following signs of symptoms associated with hyponatremia: headache, nausea/vomiting, decreased serum sodium, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of appetite, irritability, muscle weakness, muscle spasms or cramps and abnormal mental status such as hallucinations, decreased consciousness and confusion. Severe symptoms may include one or a combination of the following: seizure, coma and/or respiratory arrest. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures which could lead to coma.

3\. DDAVP should be used with caution in patients with habitual or psychogenic polydipsia who may be more likely to drink excessive amounts of water, putting them at greater risk of hyponatremia.